Coherus Oncology, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Six Months Ended | ||||||||||||
| · · June 30, · · June 30, | ||||||||||||
| · 2025 · 2024 · 2025 · 2024 | ||||||||||||
| Net revenue | | $10,254 | | $10,296 | | $17,853 | | $12,604 | ||||
| Costs and expenses: | | | | | | | | | ||||
| Cost of goods sold | | 3,395 | | 1,809 | | 6,048 | | 3,248 | ||||
| Research and development | | 26,306 | | 20,598 | | 50,662 | | 49,022 | ||||
| Selling, general and administrative | | 26,039 | | 27,515 | | 52,064 | | 67,747 | ||||
| Total costs and expenses | | 55,740 | | 49,922 | | 108,774 | | 120,017 | ||||
| Loss from operations | | (45,486) | | (39,626) | | (90,921) | | (107,413) | ||||
| Interest expense | | (2,277) | | (4,062) | | (4,427) | | (7,180) | ||||
| Loss on debt extinguishment | | | — | | | (12,630) | | | — | | | (12,630) |
| Other income (expense), net | | 2,901 | | 1,467 | | 3,088 | | 4,336 | ||||
| Loss from continuing operations before income taxes | | (44,862) | | (54,851) | | (92,260) | | (122,887) | ||||
| Income tax provision | | — | | — | | — | | — | ||||
| Net loss from continuing operations | | | (44,862) | | | (54,851) | | | (92,260) | | | (122,887) |
| Net income from discontinued operations, net of tax (Note 6) | | | 342,629 | | | 41,930 | | | 333,458 | | | 212,841 |
| Net income (loss) | | $297,767 | | $(12,921) | | $241,198 | | $89,954 | ||||
| | | | | | ||||||||
| Net income (loss) per share: | | | | | | | ||||||
| Net loss from continuing operations - basic and diluted | | $(0.39) | | $(0.48) | | $(0.80) | | $(1.08) | ||||
| Net income from discontinued operations - basic and diluted | | $2.95 | | $0.37 | | $2.88 | | $1.87 | ||||
| Net income (loss) per share - basic and diluted | | $2.57 | | $(0.11) | | $2.08 | | $0.79 | ||||
| | | | | | | | | | | | | |
| Weighted-average number of shares used in computing net income (loss) per share: | | | | | | | | | | | | |
| Basic and diluted | | | 116,077,710 | | | 114,819,965 | | | 115,968,352 | | | 113,784,636 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.